This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Phibro (PAHC) Q3 Earnings Beat Estimates, Margins Decline
by Zacks Equity Research
Phibro's (PAHC) fiscal third-quarter revenues improved year over year on growth in Performance Products and Mineral Nutrition segments.
McKesson (MCK) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter 2021 results benefit from strong performance at Medical-Surgical Solutions segment.
DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) witnesses revenue growth in each of its segments in the first quarter.
Becton Dickinson (BDX) Earnings Surpass Estimates in Q2
by Zacks Equity Research
Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal second quarter.
Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Bruker's (BRKR) robust performances across segments and geographies manage to drive its Q1 sales despite pandemic-led business challenges.
Tandem Diabetes (TNDM) Q1 Net Loss Narrows, Guidance Up
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong international and domestic pump sales and shipment boosted the first-quarter top line.
NuVasive (NUVA) Q1 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
NuVasive's (NUVA) first-quarter revenues improved year over year led by progress in U.S. procedural volumes and international business.
Cardinal Health (CAH) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results reflect weakness in Pharmaceutical segment.
Cerner (CERN) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Cerner's (CERN) first-quarter results benefit from gains in Licensed software, Subscriptions and Managed services units, and expansion in gross margin.
Allscripts (MDRX) Inches Up 0.3% on Earnings Beat in Q1
by Zacks Equity Research
Allscripts (MDRX) witnesses a year- over- year surge in earnings during Q1.
LabCorp (LH) Base Line Growth Solid, COVID-Related Sales Drop
by Zacks Equity Research
LabCorp's (LH) Walgreens-partnership expands to include new integrated digital experiences.
Myriad Genetics (MYGN) Beats on Q1 Earnings and Revenues
by Zacks Equity Research
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q1 sales despite pandemic-led business challenges.
Here's How Much You'd Have If You Invested $1000 in Boston Scientific a Decade Ago
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Exact Sciences (EXAS) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Exact Sciences' (EXAS) first-quarter 2021 revenues improved year over year led by growth in Precision Oncology, COVID-19 testing and Screening revenues.
PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results benefit from strong segmental performance.
Globus Medical (GMED) Q1 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Globus Medical's (GMED) first-quarter 2021 revenues improved year over year on strength in Enabling Technologies and U.S. Spine.
AmerisourceBergen (ABC) Q2 Earnings Beat, Revenues Miss
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal second-quarter results benefit from segmental growth.
Inogen (INGN) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Inogen (INGN) gains traction from revenue growth within its Rental segment in Q1.
PRA Health (PRAH) Stock Down 0.3% Despite Q1 Earnings Beat
by Zacks Equity Research
PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the first quarter.
Zimmer Biomet (ZBH) Q1 Earnings Top, Operating Margin Up
by Zacks Equity Research
Zimmer Biomet's (ZBH) core hip and S.E.T. business registers growth in the reported quarter.
Henry Schein (HSIC) Q1 Earnings Top Estimates, '21 EPS View Up
by Zacks Equity Research
Henry Schein (HSIC) sees robust segmental performance in Q1 boosted by strong rebound in sales, and solid demand for PPE and COVID-19-related products.
IDEXX (IDXX) Earnings Beat Estimates in Q1, '21 View Up
by Zacks Equity Research
IDEXX (IDXX) registers strong contribution from its CAG business in the first quarter despite pandemic-induced challenges.
CVS Health (CVS) Q1 Earnings Beat Estimates, EPS View Up
by Zacks Equity Research
CVS Health's (CVS) revenues across all the three operating segments improve in Q1. Increased guidance amid the pandemic scenario is another positive.
4 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Rebound in base sales make us optimistic about OMI, INGN, XRAY and CNTG's results this time around.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Stryker, Boston Scientific Corp, Intuitive Surgical and Asensus Surgical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Stryker, Boston Scientific Corp, Intuitive Surgical and Asensus Surgical